Solid biosciences provides second quarter business update and financial results

– on track to submit ind in q4 2023 for sgt-003, a next-generation gene therapy for patients with duchenne muscular dystrophy (duchenne) –
SLDB Ratings Summary
SLDB Quant Ranking